Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLYNG-1: LYN-005 in Schizophrenia/Schizoaffective Disorder
NCT05779241Phase 3Completed
- Sponsor
- Lyndra Therapeutics
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of LYN-005 in schizophrenia, schizoaffective disorder, sponsored by Lyndra Therapeutics. Started Apr 2023; status: completed.
02
Drugs
LYN-005
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT05779241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779241.